Pharmacovigilance Masterclass: Drug Safety Essentials

A detailed exploration of the QPPV role in EU pharmacovigilance, covering responsibilities, daily workflows, audit preparation, and compliance challenges.

• • Overview of PV as a continuous process

  • Pre-Clinical Development:

    • Toxicology & reproductive studies

    • Limitations of animal data

  • Clinical Trials:

    • Phase I, II, III safety monitoring

  • Regulatory Approval:

    • Benefit–risk review

    • Risk Management Plan creation

  • Post-Marketing Surveillance:

    • Ongoing monitoring & reassessment

• Definition of a safety signal (CIOMS VIII)

• Sources: spontaneous reports, literature, EHRs, social media

• Process: detection, validation, prioritization, in-depth evaluation

• Outcome: risk minimization recommendations

• Risk Identification & Assessment: frequency, severity, impact

• Minimization Tools:

  • Routine: labeling, packaging, prescription status

  • Additional: education, controlled distribution, pregnancy prevention programs

• Effectiveness Evaluation: measuring success of interventions

• Healthcare Provider Communication:

  • DHPC letters, updated prescribing info, education

• Patient Communication:

  • PPIs, medication guides, alert cards, counseling

• Regulatory Transparency:

  • Public reports, open meetings, AE databases, safety updates

• PV beyond approval – decades of monitoring

• Examples:

  • Rare adverse effects detection

  • Long-term effects and special population risks

  • Emerging interactions with new medicines

• The evolving safety profile over time

Advanced Signal Detection in Practice

This lecture takes a deep dive into one of pharmacovigilance’s most critical and technical domains—signal detection. We explore how disproportionality analysis methods, such as the Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), and Information Component (IC), are applied to large-scale safety databases like VigiBase, FAERS, and EVDAS. Through real-world examples, you’ll see how statistical signals emerge, how to interpret their clinical relevance, and how to avoid common pitfalls such as false positives that can waste resources or cause unnecessary alarm, and false negatives that may delay vital safety interventions. By the end of this lecture, you’ll understand not just the mathematics, but also the judgment and multidisciplinary collaboration needed to transform raw data into meaningful safety insights that protect patients worldwide.

Explore how pharmacovigilance systems translate safety signals into real-world interventions. This lecture presents step-by-step case studies — including SGLT2 inhibitor–associated ketoacidosis and fluoroquinolone-induced tendon rupture — to illustrate how data, analysis, and regulation merge to drive patient safety.

1. Global ADR burden and preventability

2. PV’s life-saving role

3. Vioxx case study and lessons learned

4. How PV improves evidence-based medicine, personalized therapy, and polypharmacy management

1. Direct and indirect healthcare savings

2. Efficiency gains for healthcare systems

3. Bridging PV gaps in LMICs

4. WHO initiatives, collaborations, and traditional medicine safety

In this lecture, learners gain a practical understanding of how regulators and pharmacovigilance professionals evaluate the balance between therapeutic benefits and safety risks throughout the lifecycle of a medicinal product. Using real-world examples such as COVID-19 vaccines and oncology medicines, the session introduces key tools including the BRAT framework and MCDA, and explains how benefit-risk analysis directly informs safety signal evaluation and regulatory action.

• Emerging Trends: AI & machine learning, digital reporting, big data, pharmacogenomics, global harmonization.

• Challenges Ahead: data privacy, underreporting, regulatory complexity, scientific limitations.

• Expanding Scope: herbovigilance, cosmetovigilance, materiovigilance, environmental PV.

• Education & Training: healthcare curricula, professional certifications, multidisciplinary skills.

• Empowering Patients: health literacy, active reporting, benefit–risk understanding.

• Shared Responsibility: providers, patients, industry, regulators working together.

• Summary: PV’s history, scope, ecosystem, public health impact, and global collaboration.

This lecture explains how modern PV teams use technologies like NLP and RPA to process safety reports faster and improve signal detection.

• Key historical milestones from 1848 to the present

• Evolution of PV regulations and global collaboration (WHO, EMA, FDA, ICH)

• Overview of major reporting systems (FAERS, EudraVigilance, VigiBase)

• India’s PV journey & integration of traditional medicine monitoring

• AI-powered signal detection, mobile reporting, real-time dashboards

• Measurable impacts of effective PV on public health and healthcare costs

Common misconceptions and the realities of PV

Roles of healthcare providers, patients, industry, and regulators

Practical steps for engagement and contribution to PV systems

• WHO, EMA, FDA, ISoP, CIOMS resources and educational pathways

• Emerging PV technologies and methods (precision safety, predictive models)

• The importance of collaboration for global medication safety